Key result
Atrial fibrillation catheter ablation was associated with a significant reduction in de novo dementia occurrence compared to non-ablation cohorts (HR 0.52; 95% CI 0.35-0.76).
Why the study?
AF is independently associated with cognitive decline and dementia, but the effects of AF catheter ablation on dementia prevention remain under investigation.
Does atrial fibrillation catheter ablation reduce the incidence of dementia in patients with atrial fibrillation?
Meta-Analysis (n=40,146)
Does atrial fibrillation catheter ablation reduce the incidence of dementia in patients with atrial fibrillation?
Hazard Ratio: 0.52 (95% CI 0.35–0.76)
Number Needed to Treat: 41
Catheter ablation for atrial fibrillation is associated with a nearly 50% reduction in the risk of developing dementia over a median 4.5-year follow-up compared to non-ablation strategies.
May support AFCA for dementia risk reduction in AF; leaves open need for randomized trials.
BACKGROUND: Atrial fibrillation (AF) is independently associated with the onset of cognitive decline/dementia. AF catheter ablation (AFCA) is the most effective treatment strategy in terms of sinus rhythm maintenance, but its effects on dementia prevention remain under investigation. The aim of the present study was to perform a systematic review and meta-analysis of the presently available studies exploring the effect of AFCA on dementia occurrence. METHODS: PubMed/MEDLINE databases were screened for articles through 14 March 2022 reporting adjusted time-to-event outcome data comparing AFCA and non-AFCA cohorts in terms of de novo dementia occurrence. A random effect meta-analysis was performed to estimate the meta-analytic hazard ratio (HR) of dementia occurrence in AFCA vs. non-AFCA cohorts, as well as the meta-analytic incidence rate of dementia in the non-AFCA cohort. Based on the aforementioned estimates, the number needed to treat (NNT), projected at median follow-up, was derived. RESULTS: Four observational studies were included in the analysis, encompassing 40,146 patients (11,312 in the AFCA cohort; 28,834 in the non-AFCA cohort). AFCA conferred a significant protection to the development of dementia with an overall HR of 0.52 (95% CI 0.35-0.76). The incidence rate of dementia in the non-AFCA group was 1.12 events per 100 person-year (95% CI 0.47-2.67). The derived NNT projected to the median follow-up (4.5 years) was 41. CONCLUSION: AFCA is associated with a nearly 50% reduction in dementia occurrence during a median 4.5-year follow-up. Future randomized clinical trials are needed to reinforce these findings.
No takes yet. Share an insight, caveat, or question.
Saglietto et al. (2022) conducted a meta-analysis in Atrial Fibrillation (n=40,146). Atrial fibrillation catheter ablation (AFCA) vs. Non-AFCA cohort was evaluated on De novo dementia occurrence (HR 0.52, 95% CI 0.35-0.76). Atrial fibrillation catheter ablation was associated with a significant reduction in de novo dementia occurrence compared to non-ablation cohorts (HR 0.52; 95% CI 0.35-0.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: